Skip to main content

Table 2 Alterations in microarchitectural properties of trabecular bone of the femur distal metaphysis.

From: Soy isoflavones avert chronic inflammation-induced bone loss and vascular disease

Treatment

BV/TV (%)A

TbN (1/mm3)B

TbSp (mm)C

TbTh (mm)D

Conn Den (1/mm3)E

SMIF

Linear Attenuation

0 IF Placebo

8.80 ± 0.01a

3.89 ± 0.15a, c

0.27 ± 0.01a

0.051 ± 0.001

58.97 ± 8.14a

2.63 ± 0.10

1.01 ± 0.02

0 IF LPS

6.34 ± 0.01b

3.25 ± 0.15b

0.32 ± 0.01b, d

0.052 ± 0.001

40.56 ± 8.80a, b

2.83 ± 0.15

0.90 ± 0.06

126 IF Placebo

8.80 ± 0.01a

3.92 ± 0.10a

0.26 ± 0.01a

0.050 ± 0.002

47.33 ± 6.72a, b

2.91 ± 0.16

1.01 ± 0.02

126 IF LPS

6.52 ± 0.01b

3.41 ± 0.13b, e

0.30 ± 0.01b, c, d

0.050 ± 0.001

33.56 ± 3.80b

3.02 ± 0.05

0.95 ± 0.02

504 IF Placebo

7.14 ± 0.01a, b

3.50 ± 0.17b, c, d

0.29 ± 0.02a, d

0.050 ± 0.001

34.12 ± 4.99b

2.96 ± 0.14

0.96 ± 0.03

504 IF LPS

8.40 ± 0.01a, b

3.71 ± 0.14a, d, e

0.28 ± 0.01a, c

0.053 ± 0.002

52.12 ± 8.87a, b

2.93 ± 0.15

1.00 ± 0.02

P value

       

LPS

0.0731

0.0085

0.119

0.2834

0.4317

0.3779

0.1018

IF

0.9681

0.7839

0.5918

0.2478

0.4208

0.1493

0.6326

LPS*IF

0.0397

0.0099

0.0124

0.6706

0.0341

0.6773

0.0613

  1. Mice were fed soy isoflavones (IF; 0, 126 or 504 mg aglycone equivalents of IF/kg diet) for 14-days prior to and during a 30-day exposure to LPS (1.33 μg/d). Results are expressed as means ± standard error. (A) trabecular bone volume (BV/TV), (B) trabecular number (TbN), (C) trabecular separation (TbSp), and (D) trabecular thickness (TbTh), (E) Connective Density (Conn Den), (F) Structure Model Index (SMI). Values for a given parameter that share the same superscript letter are not statistically different (P > 0.05) from each other.